Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biovail Cardizem XL NDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Biovail submits NDA for the calcium channel blocker Cardizem XL Aug. 23 for treatment of hypertension. The once-daily, graded-release diltiazem formulation "uses a unique dissolution profile, in conjunction with nighttime dosing, to address the body's typical 24-hour circadian variation in blood pressure," the firm says. In Phase III trials comparing nighttime and daytime administration, evening use resulted in "statistically significant and clinically meaningful reductions in diastolic and systolic blood pressure" between 4 a.m. and 12 noon, "the time of day when patients are at the greatest risk of having an adverse cardiac event," the firm said. Biovail received approval in January 2000 for an earlier generation extended-release diltiazem without nighttime dosing. That formulation was never marketed
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS001591

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel